BridgeMD
New treatment option for Tobacco Use Disorder
Official title Accelerated dTMS Smoking Cessation
ClinicalTrials.gov ID: NCT07292883
What this study is testing
- What it's testing
- The goal of this clinical trial is to examine whether a 5-day course of bilateral accelerated deep transcranial magnetic stimulation (aTMS) is a feasible treatment to help adults (18-65) with Tobacco Use Disorder to quit smoking. This study aims to enroll 30-40 participants and will examine treatment tolerability, treatment acceptability, participant retention, and adherence to scheduled treatment sessions.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged 18 years or older;
- Tobacco use disorder as assessed by DSM-5;
- Fagerstrom Test of Nicotine Dependence (FTND) ≥ 4;
- Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of ≥ 7;
- Must sign and date the informed consent form;
You likely can't join if
- Reported smoking abstinence in the 3 months preceding screening visit;
- Current use of other smoking cessation aids;
- Contraindication to rTMS;
- Pregnancy, trying to become pregnant or breastfeeding;
- Current or recent history of cerebrovascular disease;
- Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the study at PI (or its delegate) discretion;
See the full eligibility criteria
- Aged 18 years or older;
- Tobacco use disorder as assessed by DSM-5;
- Fagerstrom Test of Nicotine Dependence (FTND) ≥ 4;
- Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of ≥ 7;
- Must sign and date the informed consent form;
- Stated willingness to comply with all study procedures.
- Able to communicate in English.
- Reported smoking abstinence in the 3 months preceding screening visit;
- Current use of other smoking cessation aids;
- Contraindication to rTMS;
- Pregnancy, trying to become pregnant or breastfeeding;
- Current or recent history of cerebrovascular disease;
- Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the study at PI (or its delegate) discretion;
- Serious current or personal history of medical condition/disease (neurological disorders, brain lesions, multiple sclerosis, head trauma, loss of consciousness, hearing loss, etc.) preventing same inclusion as per PI...
- Current, personal history or family history of seizures;
- Concomitant use of medication that lowers seizure threshold, such as clozapine;
- Concomitant use of more than 2 mg lorazepam (or an equivalent) or any anticonvulsants.
The study team makes the final eligibility decision.
Where it's taking place
- Penetanguishene, Ontario, Canada
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Penetanguishene, Ontario, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.